Search

Bi2Te3‐based materials have drawn much attention from the thermoelectric community due to their excellent thermoelectric performance near room temperature. However, the stability of existing n‐type Bi2(Te,Se)3 materials is still low due to the evaporation energy of Se (37.70 kJ mol−1) being much lower than that of Te (52.55 kJ mol−1). The evaporated Se from the material causes problems in interconnects of the module while degrading the efficiency. Here, we have developed a new approach for the high‐performance and stable n‐type Se‐free Bi2Te3‐based materials by maximizing the electronic transport while suppressing the phonon transport, at the same time. Spontaneously generated FeTe2 nanoinclusions within the matrix during the melt‐spinning and subsequent spark plasma sintering is the key to simultaneous engineering of the power factor and lattice thermal conductivity. The nanoinclusions change the fermi level of the matrix while intensifying the phonon scattering via nanoparticles. With a fine‐tuning of the fermi level with Cu doping in the n‐type Bi2Te3–0.02FeTe2, a high power factor of ~41 × 10−4 Wm−1 K−2 with an average zT of 1.01 at the temperature range 300–470 K are achieved, which are comparable to those obtained in n‐type Bi2(Te,Se)3 materials. The proposed approach enables the fabrication of high‐performance n‐type Bi2Te3‐based materials without having to include volatile Se element, which guarantees the stability of the material. Consequently, widespread application of thermoelectric devices utilizing the n‐type Bi2Te3‐based materials will become possible. [ABSTRACT FROM AUTHOR]

Aim: This study aimed to evaluate the safety and efficacy of 131I‐rituximab in patients with relapsed or refractory follicular or mantle cell lymphoma. Methods: Twenty‐four patients with relapsed or refractory follicular or mantle cell lymphoma were administered unlabeled rituximab (70 mg) immediately before receiving a therapeutic dose of 131I‐rituximab. Contrast‐enhanced 18F‐fluorodeoxyglucose positron emission tomography/computed tomography was used a month later to assess tumor response. Results: This study enrolled 24 patients between June 2012 and 2022. Depending on how they responded to radioimmunotherapy (RIT), 131I‐rituximab was administered one to five times. Of the 24 patients, 9 achieved complete response after RIT and 8 achieved partial response. The median progression‐free and overall survival was 5.9 and 37.9 months, respectively. During the follow‐up period of 64.2 months, three patients were diagnosed with a secondary malignancy. Among treatment‐related adverse events, hematologic toxicities were common, and grade 3–4 thrombocytopenia and neutropenia were reported in 66.6% of cases. Conclusion: 131I‐rituximab has an effective and favorable safety profile in patients with relapsed or refractory follicular lymphoma and mantle cell lymphoma. This suggests that RIT may also be considered a treatment option for patients with relapsed or refractory follicular lymphoma and mantle cell lymphoma. [ABSTRACT FROM AUTHOR]

Introduction: The role of inflammation in the pathophysiology of polycythemia vera (PV) is important. The presence of JAK2 mutations is important in the diagnosis of PV, and serum levels of erythropoietin (EPO) also play a supporting role. However, serum EPO levels show some limitations. The neutrophil‐to‐lymphocyte ratio (NLR) and platelet‐to‐lymphocyte ratio (PLR) are a readily available marker of inflammation. Thus, we examined whether NLR & PLR might diagnose PV in erythrocytosis patients. We compared NLR & PLR and EPO diagnostic values. Methods: We retrospectively reviewed clinical and laboratory data from two referral hospitals. Two hundred and eighty‐five patients with erythrocytosis who underwent a test for the JAK2 mutation were included. It wac classified as the PV group and the secondary polycythemia (SP) group. Results: The median NLR & PLR in the PV group (n = 70) was significantly higher than that in the SP group (n = 170) (NLR: 6.04 vs. 1.77, PLR: 283.18 vs. 101.56, respectively, p < 0.001). In the receiver operating characteristic analysis, the area under the curve of NLR & PLR was significantly higher than that of serum EPO (NLR vs EPO: 0.921 vs. 0.827, p = 0.003; PLR vs EPO: 0.917 vs 0.827, p = 0.003). Conclusion: In conclusion, NLR & PLR were higher in PV than in SP and showed better diagnostic value than serum EPO level, highlighting their potential as minor diagnostic criteria in patients with PV. [ABSTRACT FROM AUTHOR]

Lithium (Li) is the "holy grail" for satisfying the increasing energy demand. This is because of its high theoretical capacity and low potential. Although Li is considered as a potential anode material, dendritic Li growth and the limited electrochemical properties continue to hinder its practical application. Structure‐based self lithium ion (Li+) concentrating electrodes with high capacity and uniform Li+‐flux are recommended to overcome these shortcomings of Li. However, recent studies have been limited to structural perspectives. In addition, the electrokinetic principle of electrode materials remains a challenge. Herein, the space‐confinement‐based strategy is suggested for condensed Li+‐flux control in nanoscaled slit spaces that induce the dense Li growth on an anodeless electrode by using the stratified carbon pack (SCP). The micro/mesoporous slits of the SCP concentrate the electric field, which is strengthened by the space‐confined electric field focusing, resulting in the accumulation of Li+‐flux in the host. The accumulated Li+ in host sites enables a uniform Li deposition with high capacity at high current density stably. Furthermore, SCPs have great compatibility with LiNi0.8Co0.1Mn0.1O2 (NCM811) cathode, representing the outstanding full cell performance with Li deposited electrode which show the high specific of 115 mAh g−1 at 4 C during 350 cycles. [ABSTRACT FROM AUTHOR]

With the increasing demand for green energy vehicles, lithium‐sulfur batteries are drawing attention as new energy storage devices. This is because the theoretical capacity of sulfur cathodes is least five times higher that of conventional cathodes. However, in combination with lithium, sulfur cathodes diffuse to all parts of the cell through an uncontrolled and irreversible shuttle effect. Various studies have attempted to confine sulfur in a particular structure while it is dissolved in electrolytes. Unfortunately, this approach is ineffective because of the mobility and corrosive properties of lithium polysulfide. In this study, we present nano‐conductive additives with minimized interfacial energy to lithium polysulfide that controls the shuttle effect by confining the movement of the lithium polysulfide solution within the cathodes. The nano‐conductive additive was synthesized to form low interfacial energy through surface modification and used in lithium‐sulfur batteries to enable a capacity of approximately 600 mAh g−1 for 1000 repeated charge/discharge cycles. [ABSTRACT FROM AUTHOR]

Electrochemical carbon dioxide reduction reaction (CO2RR) is a promising approach to mitigate CO2 concentration and generate carbon feedstock. Recently, the (sub‐)nanometer design of catalyst structures has been revealed as an efficient means to control the reaction process through the local reaction environment. Herein, the synthesis of a novel tin oxide (SnOx) nanoparticle (NP) catalyst with highly controlled sub‐nanoscale interplanar gaps of widths <1 nm (SnOx NP‐s) is reported via the lithium electrochemical tuning (LiET) method. Transmission electron microscopy (TEM) and 3D‐tomo‐scanning TEM (STEM) analysis confirm the presence of a distinct segmentation pattern and the newly engineered interparticle confined space in the SnOx NP‐s. The catalyst exhibits a significant increase in CO2RR versus hydrogen evolution selectivity by a factor of ≈5 with 20% higher formate selectivity relative to pristine SnO2 NPs at −1.2 VRHE. Density functional theory calculations and cation‐size‐dependent experiments indicate that this is attributable to a gap‐stabilization of the rate‐limiting *OCHO and *COOH intermediates, the formation of which is driven by the interfacial electric field. Moreover, the SnOx NP‐s exhibits stable performance during CO2RR over 50 h. These results highlight the potential of controlled atomic spaces in directing electrochemical reaction selectivity and the design of highly optimized catalytic materials. [ABSTRACT FROM AUTHOR]

To secure the economic feasibility of electrochemical carbon dioxide reduction reaction (CO2RR), a method of using support materials to reduce the amount of catalyst loading and increase catalytic activity for CO2RR can be a solution. Herein, guidelines for selecting carbon support materials suitable for CO2RR are reported. In a gaseous CO2‐fed CO2RR electrolyzer, an Ag nanoparticle‐composited carbon nanocage (denoted as Ag/CNC) electrode exhibits an optimal performance for CO2RR with a partial current density of ≈400 mA cm−2. Ag/CNC showcases a uniformly dispersed morphology with Ag nanoparticles and sufficient hydrophobicity after the reaction to prevent flooding, which is known to inhibit the mass transfer of CO2. Furthermore, the CNCs possess small amounts of carbon defects; this suppresses the catalytic activity for the hydrogen evolution reaction (HER), which is a side reaction of CO2RR. Results of a three‐stack cell experiment with the Ag/CNC electrode reveal the possibility of a support‐based strategy for achieving an industrial‐level scaling of CO2RR. This study suggests that the support material for CO2RR should be considered not only on the basis of the morphology of carbon, uniform dispersion of Ag nanoparticles, and hydrophobicity of the electrode but also factors influencing the HER, such as carbon defects. [ABSTRACT FROM AUTHOR]

Copper (Cu) offers a means for producing value‐added fuels through the electrochemical reduction of carbon dioxide (CO2), i.e., the CO2 reduction reaction (CO2RR), but designing Cu catalysts with significant Faradaic efficiency to C2+ products remains as a great challenge. This work demonstrates that the high activity and selectivity of Cu to C2+ products can be achieved by atomic‐scale spacings between two facets of Cu particles. These spacings are created by lithiating CuOx particles, removing lithium oxides formed, and electrochemically reducing CuOx to metallic Cu. Also, the range of spacing (ds) is confirmed via the 3D tomographs using the Cs‐corrected scanning transmission electron microscopy (3D tomo‐STEM), and the operando X‐ray absorption spectra show that oxidized Cu reduces to the metallic state during the CO2RR. Moreover, control of ds to 5–6 Å allows a current density exceeding that of unmodified CuOx nanoparticles by about 12 folds and a Faradaic efficiency of ≈80% to C2+. Density functional theory calculations support that ds of 5–6 Å maximizes the binding energies of CO2 reduction intermediates and promotes C–C coupling reactions. Consequently, this study suggests that control of ds can be used to realize the high activity and C2+ product selectivity for the CO2RR. [ABSTRACT FROM AUTHOR]

A nitrogen‐rich nanotube with open mesopore channels to its internal compartments is reported to enable high‐performance lithium ion hybrid capacitors, which show high energy densities (274–127 W h kg−1) exceeding the energy density of even a supercapacitor more than ten‐folds, at a power density of 153–22800 W kg−1, along with fast rate capability over robust discharge and charge cycles. [ABSTRACT FROM AUTHOR]

This study aimed to determine the objective response, toxicity, and clinical outcome of weekly rituximab consolidation after four cycles of R- CHOP21 in very elderly patients with DLBCL. A prospective, multi-institutional phase II trial was conducted on patients with previously untreated CD20+ DLBCL who were older than 70 yr. Patients were treated with four cycles of R- CHOP21 followed by weekly consolidation with rituximab (375mg/m2, four times infusion) ( NCT01181999). We also compared the clinical outcomes with an historical case-matched control group treated conventionally with six cycles of R- CHOP21. A total of 51 patients with newly diagnosed DLBCL were enrolled at 15 institutes between June 2010 and September 2013 . The median age was 76 yr (range: 70-89). Forty-one of the 51 patients completed the planned rituximab consolidation (R-consolidation). The overall response rate was 78.4%, comprising 74.5% with a complete response and 3.9% with a partial response. After a median follow-up of 20.3 months, 2-yr progression-free survival and overall survival were 63.9% and 68.7%, respectively. No serious toxicities were reported during rituximab consolidation. Weekly rituximab consolidation following four cycles of R- CHOP21 resulted in an acceptable response with high tolerability and could be a good compromise between efficacy and safety for elderly patients with DLBCL. [ABSTRACT FROM AUTHOR]

The lithium polysulfide solution from the fountain flows along a road paved with two different additives, which describes the state of the electrodes that can be caused by the differences in the additives. Keywords: interfacial energy; Li-S battery; nano-conductive additive; surface energy; surface modification EN interfacial energy Li-S battery nano-conductive additive surface energy surface modification 1 1 1 04/11/22 20220401 NES 220401 B The Cover Feature b shows a nano-conductive additive that increases reversibility through low interfacial energy with lithium polysulfide in repeated reactions of a lithium-sulfur battery. Cover Feature: Nano-Conductive Additive with Low Interfacial Energy Confining the Movement of Lithium Polysulfide Solution Enables Stable Reaction of Sulfur Electrode in Lithium-Sulfur Batteries (Batteries & Supercaps 4/2022). [Extracted from the article]

A correction is presented to the article "Enhancement of Catalytic Activity and Selectivity for the Gaseous Electroreduction of CO2 to CO."

Keywords: 3D tomography; density functional theory; electrochemical carbon dioxide reduction; space confinement; sub-nanospacing EN 3D tomography density functional theory electrochemical carbon dioxide reduction space confinement sub-nanospacing 1 1 1 02/21/22 20220222 NES 220222 B 3D Tomography b In article number 2107349, Stefan Ringe, Youngkook Kwon, Hyung Mo Jeong, and co-workers suggest a new catalytic carbon dioxide reduction reaction (CO SB 2 sb RR) environment, sub-nano scale spacing within Sn nanoparticles, which is achieved by a Li electrochemical tuning method. In this small spacing structural environment, space confinement induces enhances the activity and selectivity of CO SB 2 sb RR by stabilization of rate-limiting intermediates, resulting in effectively suppressed hydrogen evolution reaction. 3D tomography, density functional theory, electrochemical carbon dioxide reduction, space confinement, sub-nanospacing. [Extracted from the article]

Primary breast diffuse large B-cell lymphoma (DLBCL) is an extremely rare presentation of non-Hodgkin's lymphoma that has been associated with poorer clinical outcomes compared with nodal DLBCL in the pre-rituximab era. The aim of this study was to investigate the impact of rituximab on clinical outcomes in patients with primary breast DLBCL. Data from 25 female patients with primary breast DLBCL receiving rituximab plus chemotherapy were matched to 75 female patients (1:3) with nodal DLBCL by following five established prognostic factors (age, Ann Arbor stage, Eastern Cooperative Oncology Group performance status, serum lactate dehydrogenase level and B symptoms). Overall survival (OS) was similar between primary breast and nodal DLBCL groups (3-year OS rate, 82.2% vs. 90.7%, respectively; p = 0.345). In the analysis of immunohistochemically defined prognostic subgroups, 19 of 20 available cases in the primary breast DLBCL group displayed a non-germinal center (GC) phenotype. Compared with patterns of recurrence, extranodal progression in the breast or central nervous system (CNS) was significantly higher in the primary breast DLBCL group than in the nodal DLBCL group ( p < 0.001). Additionally, the stage-modified International Prognostic Index was the only independent prognostic factor for OS in this population. This suggests that clinical outcomes of primary breast DLBCL might no longer be inferior to those of nodal DLBCL in the rituximab era, which might be associated with the intrinsic biologic characteristics of the non-GC phenotype. However, despite including rituximab, extranodal progression in the breast or CNS was problematic. This study was registered at as no. NCT01266668. [ABSTRACT FROM AUTHOR]

Stage IV marginal zone B-cell lymphomas (MZL) are detected in more than 25% of lymphoma patients. In this study, we conducted retrospective analyses of specific cases of stage IV MZL in order to assess their clinical features, as well as the treatments and prognoses of these cases. A total of 94 patients with histological diagnosis of stage IV-MZL from 17 different institutions in Korea were included. Multiple-mucosa-associated lymphoid tissue (MALT)-organs-involved MZL (M-MZL) was detected in 34 patients (36.2%). Bone-marrow-involved stage IV MZL (BM-MZL) was detected in 33 patients (35.1%). Median time to progression (TTP) was 2.4 years (95% CI, 1.9-2.9). Five- and 10-year overall survival rates were 84.5% and 79.8%, respectively. Patients with lymph node involvement in stage IV MZL appeared to have worse prognoses in TTP ( P = 0.015). Thirty-one patients were treated with a regimen including rituximab (CTx-R[+]), and 31 with a regimen that did not include rituximab (CTx-R[−]). The CTx-R(+) group showed better responses than the CTx-R(−) group (83.9% versus 54.8%, P = 0.026). However, no differences in TTP duration were detected ( P = 0.113). Stage IV MZL tend to follow an indolent disease course. Therefore, lymph node involvement is a more valuable prognostic factor for TTP. Rituximab appears to contribute to better responses, but not in cases of TTP. ( Cancer Sci 2010; 101: 2443-2447) [ABSTRACT FROM AUTHOR]

Summary The optimal treatment strategy for newly diagnosed primary central nervous system lymphoma (PCNSL) has yet to be established, especially in the elderly. In the current study, we conducted a phase II study to evaluate the efficacy and safety of rituximab plus high‐dose MTX followed by rituximab plus cytarabine in patients aged ≥60 years newly diagnosed with PCNSL. Patients received an induction treatment of high‐dose methotrexate plus rituximab followed by two cycles of a consolidation treatment of cytarabine plus rituximab. The primary end‐point was a 2‐year progression‐free survival (PFS) rate. A total of 35 patients were recruited, and their median age was 73 (range: 60–81). After induction treatment, the complete and partial responses (PRs) were 56% and 20% respectively. Twenty‐six patients proceeded to the consolidation treatment; the complete and PRs were 59% and 9% respectively. After a median follow‐up duration of 36.0 months, the 2‐year PFS rate was 58.7%. Treatment was generally well‐tolerated as only three patients were withdrawn from the study due to toxicity, and no treatment‐related mortality was reported. The 2‐year overall survival rate was 77.9%. The current study may suggest the feasibility of administering high‐dose MTX plus cytarabine in PCNSL patients aged ≥60 years and the potential role of additive rituximab. [ABSTRACT FROM AUTHOR]

Keywords: 3D tomography; Cu nanoparticles; C2+ fuels; CO2 reduction, C-C coupling reactions In article number 1903423, Jeung Ku Kang and co-workers describe Cu nanoparticles with atomic-scale spacings. 3D tomography, Cu nanoparticles, C2+ fuels, CO2 reduction, C-C coupling reactions. [Extracted from the article]

In article number 1601355, Jeung Ku Kang and co‐workers describe high‐performance hybrid fullcell capacitors on new paradigm structures where metals‐encapsulated nitrogen‐rich nanotubes (NRTs) and pristine NRTs are employed as negative and positive electrodes of a hybrid full‐cell capacitor. Indeed, assembling both electrodes into the fullcell device is shown to exhibit the energy density exceeding that of even a supercapacitor by more than 10‐folds, together with excellent capacity retention over robust cycle life. In addition, the maximum power density achieved is about 100‐folds higher than those of commercial lithium‐ion batteries. [ABSTRACT FROM AUTHOR]

Objectives: (1) Evaluate the influence of tinnitus upon the auditory spectral and temporal resolution. (2) Evaluate the effect of tinnitus on speech perception ability in noise. Methods: To exclude the effect of decreased hearing threshold, unilateral idiopathic tinnitus patients with symmetric hearing threshold were enrolled. The subjects were 13 patients with symmetric hearing loss >20 dB HL and binaural difference <10 dB at 0.25, 0.5, 1, 2, 3, 4, and 8 kHz, or who have normal hearing threshold and binaural difference <10 dB at 0.25, 0.5, 1, 2, 3, 4, and 8 kHz, and threshold discrepancies <15 dB at 9, 11.2, 12.5, 14, 16, 18, and 20 kHz. A total of 13 volunteers with normal hearing were enrolled as a control group. Four different psychoacoustic measurements were performed: (1) spectral‐ripple discrimination, (2) temporal modulation detection, (3) Schroeder‐phase discrimination, and (4) word recognition in noise. Results: There were no significant differences in spectral‐ripple threshold, temporal modulation detection threshold, and Schroeder‐phase discrimination between affected sides and non‐affected sides of unilateral tinnitus patients. For the word in noise test, affected sides showed worse signal‐to‐noise ratio compared to non‐affected side. Conclusions: We could not find any evidence that the tinnitus‐affected ears show worse spectral and temporal processing compared with nontinnitus ears in unilateral tinnitus patients. The spectral ripple discrimination data suggests that the tinnitus‐affected ear does not have more damage in its cochlea (especially the outer hair cell) causing the auditory filters to broaden compared with the nonaffected ear with the same hearing threshold. [ABSTRACT FROM AUTHOR]

A novel conjugated polymer, poly(4‐(4,8‐bis(5‐(2‐ethylhexyl)thiophen‐2‐yl)benzo[1,2‐b:4,5‐b']dithiophen‐2‐yl)‐2,6‐dioctylbenzo[1,2‐d:4,5‐d']bis(oxazole)) (PBB), is synthesized for use in ultrafast‐response organic photodetectors (OPDs). The PBB synthesis is considered facile because a monomer could be isolated without column chromatography purification. The excellent solubility of PBB allows easy dissolution in both halogenated and nonhalogenated solvents, facilitating the fabrication of p‐n heterojunction OPDs based‐on PBB and 6,6‐phenyl‐C71‐butyric acid methyl ester (PC71BM) using either chloroform (CF) or o‐xylene (Xy). Notably, Xy‐processed OPDs show superior performance with a responsivity (R) of 0.385 A W−1 and specific detectivity (D*) of 1.33 × 1013 Jones at –1 V, whereas CF‐based devices showed an R of 0.349 A W−1 and D* of 5.86 × 1012 Jones. More importantly, Xy‐processed OPDs exhibited an ultrafast signal response time of 3 µs, which is much faster than that of CF‐processed OPDs (42 µs). These superior static and dynamic properties of PBB:PC71BM devices are achieved by the inverted hierarchical arrangement of PBB and PC71BM via a biased orientation of PC71BM toward the ZnO layer as well as a homogenous nanomorphology. This ideal morphology is spontaneously induced due to the difference in interfacial energy between PBB and PC71BM toward the ZnO surface and a well‐mixed PBB:PC71BM blend in Xy solvent. [ABSTRACT FROM AUTHOR]

The effects of imatinib plus chemotherapy were assessed in 87 patients with newly diagnosed Philadelphia chromosome-positive (Ph(+) ) acute lymphoblastic leukemia (ALL). Imatinib was administered continuously, starting from the eighth day of remission induction chemotherapy, then through five courses of consolidation or until allogeneic hematopoietic cell transplantation (HCT). Patients who were not transplanted were maintained on imatinib for 2 years. Eighty-two patients (94.3%) achieved complete remission (CR). Among these 82 CR patients, 40 experienced recurrence of leukemia. The 5-year relapse free survival (RFS) rate and overall survival (OS) rates were 39.0% and 33.4%, respectively. In total, 56 patients underwent allogeneic HCT in first CR. The 5-year cumulative incidence of relapse and OS rate of them were 59.1% and 52.6%, respectively. Six of seven patients who were maintained on imatinib after completion of consolidation relapsed and the median time of RFS was 40.7 months. In total patient, cumulative molecular CR rate was 88.5% and median time of molecular CR duration was 13 months. Initial imatinib dose intensity was significantly associated with median CR duration (P < 0.0001), and overall survival (P = 0.002). During the initial phase of treatment of patients with Ph(+) ALL, it is important to maintain imatinib dose intensity., (© 2015 Wiley Periodicals, Inc.)